Maravai LifeSciences Holdings, Inc. — Q1 2022 10-Q
Reporting period: Three months ended March 31, 2022; unaudited results compared with Q1 2021 (prior-year figures adjusted for lease-accounting adoption). Maravai supplies products used in drug, vaccine, diagnostic and biologics development. Its two current segments are Nucleic Acid Production and Biologics Safety Testing; Protein Detection was divested in September 2021.
Financial performance
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $244.3 million | $148.2 million | +64.8% |
| Gross profit / gross margin | $204.3 million / 83.6% | $116.8 million / 78.8% | Margin expanded |
| Operating income | $167.4 million | $91.2 million | +83.5% |
| Net income | $146.9 million | $75.5 million | +94.6% |
| Net income attributable to Maravai Holdings | $66.9 million | $23.1 million | +189.4% |
| Class A EPS, basic / diluted | $0.51 / $0.50 | $0.24 / $0.24 | |
| Operating cash flow | $162.3 million | $38.3 million | |
| Adjusted EBITDA | $187.0 million | $100.9 million | +85.3% |
| Adjusted Free Cash Flow | $182.5 million | $96.4 million |
Adjusted EBITDA and Adjusted Free Cash Flow are non-GAAP measures. Adjusted Free Cash Flow is defined as Adjusted EBITDA less capital expenditures; it is not operating cash flow.
Revenue and margins
- Nucleic Acid Production revenue grew 80.5% to $223.7 million, accounting for 91.5% of total revenue. Management cited strong CleanCap and mRNA demand, including COVID-19 vaccine production, and broader use of mRNA technology.
- Biologics Safety Testing revenue rose 17.0% to $20.6 million, supported by demand in cell and gene therapy, biosimilar and other biologic programs.
- Cost of revenue rose 27.5%, slower than sales growth; management attributed gross-margin expansion primarily to favorable product mix.
Cash, liquidity and debt
- Cash was $431.5 million at March 31, down from $551.3 million at year-end. Current assets were $619.1 million and current liabilities $86.7 million.
- Investing cash outflow was $241.6 million, principally $238.8 million net cash paid for MyChem. Financing cash outflow was $40.5 million, mainly tax distributions to non-controlling owners.
- Debt principal was $542.6 million; balance-sheet debt, net of issuance costs, was $529.9 million. No revolving-credit borrowings were outstanding. The term loan matures in October 2027; its stated rate was 3.50% at quarter-end.
- In January, Maravai refinanced its term loan, moved from LIBOR to SOFR-based pricing and reduced interest margins. Management said the company was in compliance with debt covenants and its first-lien net leverage ratio was below 4.25:1.00.
- The company reported a $746.0 million Tax Receivable Agreement (TRA) liability. The agreement generally requires payments to former owners equal to 85% of certain realized or deemed tax benefits.
Material changes and unusual items
- Maravai acquired MyChem on January 27 for total consideration of $257.8 million, including $240.0 million cash paid at closing. The acquisition added $123.4 million of identifiable intangible assets and $130.8 million of goodwill. MyChem’s reported Q1 contribution to revenue and earnings was immaterial.
- MyChem consideration includes up to $40.0 million in performance payments tied to 2022 revenue targets, a $20.0 million retention payment contingent on two years of continued employment, and up to $10.0 million linked to acquired-inventory calculations. Some amounts are not included in the contractual-obligations table because payment timing or triggering events are uncertain.
- Reported Q1 SG&A included $3.0 million in MyChem transaction costs; management also cited acquisition-related costs, Vector-sale working-capital adjustments, M&A diligence and refinancing fees. Q1 included a $0.2 million debt-extinguishment loss.
- Weighted-average diluted Class A shares increased to 255.3 million from 96.7 million, principally reflecting assumed conversion of Class B shares/Topco LLC interests. Basic and diluted EPS are therefore not directly comparable without considering the capital structure.
Outlook, commentary and risks
- Management stated cash on hand, operating cash generation and credit-facility access should be sufficient for cash requirements over the next 12 months and beyond. It projected 2022 capital expenditures of $65–$75 million, primarily for new facilities in San Diego and Leland, North Carolina. The filing provides no specific revenue or earnings guidance.
- Management said COVID-19-related products and services comprised the majority of recent-period revenue. Demand could decline materially as the pandemic or vaccine demand subsides; timing and duration are uncertain and depend on factors outside the company’s control.
- Customer concentration is significant: BioNTech represented 40.4% and Pfizer 29.5% of Q1 revenue. Management also identified reliance on a limited number of customers and suppliers, competition, product quality and regulatory risks, and supply-chain, labor and inflation pressures.
- Variable-rate debt creates interest-rate exposure despite a $415 million interest-rate cap that expires March 31, 2023. The filing estimates a hypothetical 100-basis-point rate move would have changed quarterly interest expense by about $1.4 million.
- TRA payments, tax distributions, acquisition-related contingent obligations and planned facility spending are significant demands on liquidity. An early TRA termination or change of control could accelerate payments and adversely affect liquidity. Management reported no material litigation and effective disclosure controls; MyChem financial-reporting controls were still being integrated.
Investor verification priorities
- Track COVID-19-linked demand, mRNA product sales and customer concentration, particularly BioNTech and Pfizer.
- Review cash conversion and working-capital movements alongside reported earnings and non-GAAP cash-flow measures.
- Monitor MyChem integration, purchase-accounting adjustments, revenue milestones, retention conditions and potential additional payments.
- Assess debt exposure, covenant compliance, interest-rate protection and the scale and timing of TRA and tax-distribution payments.
- Compare actual facility spending with the $65–$75 million 2022 capital-expenditure projection and evaluate whether capacity investment supports demand beyond COVID-19 programs.